Evolocumab is a monoclonal antibody as well as an inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein targeting LDL receptors. Inhibition of PCSK9 could prevent LDL receptors from degradation and promote the removal of LDL-C from blood circulation. Evolocumab is used for the treatment of hyperlipidemia.